[go: up one dir, main page]

MX2010008864A - Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta 2. - Google Patents

Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta 2.

Info

Publication number
MX2010008864A
MX2010008864A MX2010008864A MX2010008864A MX2010008864A MX 2010008864 A MX2010008864 A MX 2010008864A MX 2010008864 A MX2010008864 A MX 2010008864A MX 2010008864 A MX2010008864 A MX 2010008864A MX 2010008864 A MX2010008864 A MX 2010008864A
Authority
MX
Mexico
Prior art keywords
group
aryl
monocyclic
optionally substituted
carbon atom
Prior art date
Application number
MX2010008864A
Other languages
English (en)
Inventor
Maria Prat Quinones
Maria Isabel Crespo Crespo
Carlos Puig Duran
Daniel Perez Crespo
Laia Sole Feu
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2010008864A publication Critical patent/MX2010008864A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) (ver fórmulala (I) en donde: R1 es un grupo seleccionado de -CH2OH, -NHCOH y R2 es un átomo de hidrógeno; o R1 junto con R2 forman el grupo -NHC(O)CH=CH-, en donde el átomo de nitrógeno está unido al átomo de carbono del anillo de fenilo al que está unido R1 y el átomo de carbono está unido al átomo de carbono del anillo de fenilo al que está unido R2 R3a y R3b se seleccionan independientemente del grupo que consiste en átomos de hidrógeno y grupos alquilo C1-4 n es un número entero seleccionado de 0 a 6, R4 se selecciona del grupo que consiste en un grupo cicloalquilo C3-10 monocíclico o policíclico opcionalmente sustituido, un grupo arilo C5-10 monocíclico opcionalmente sustituido y un grupo metilo que está sustituido con uno o más sustituyentes seleccionados de grupos arilo C5-10 y ariloxi C5-10, en donde los grupos cicloalquilo C3-10 monocíclicos o policíclicos y los grupos arilo C5-10 monociclicos independientemente están opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halógeno, grupos alquilo C1-4, alcoxi C1-4, arilo C5-10 y ariloxi C5-10, o una sal o solvato o estereoisómero del mismo farmacéuticamente aceptables.
MX2010008864A 2008-02-28 2009-02-27 Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta 2. MX2010008864A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08382008A EP2096105A1 (en) 2008-02-28 2008-02-28 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
PCT/EP2009/001431 WO2009106351A1 (en) 2008-02-28 2009-02-27 Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the b2 adrenergic receptor

Publications (1)

Publication Number Publication Date
MX2010008864A true MX2010008864A (es) 2010-09-07

Family

ID=39645317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008864A MX2010008864A (es) 2008-02-28 2009-02-27 Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta 2.

Country Status (15)

Country Link
US (1) US20110028442A1 (es)
EP (2) EP2096105A1 (es)
JP (1) JP2011517316A (es)
KR (1) KR20100138886A (es)
CN (1) CN101939291A (es)
AU (1) AU2009218688A1 (es)
CA (1) CA2716397A1 (es)
CO (1) CO6251284A2 (es)
EC (1) ECSP10010431A (es)
IL (1) IL206236A0 (es)
MX (1) MX2010008864A (es)
NZ (1) NZ586049A (es)
RU (1) RU2010139571A (es)
WO (1) WO2009106351A1 (es)
ZA (1) ZA201004009B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3104246A (en) * 1961-08-18 1963-09-17 Roussel Uclaf Process of preparation of beta-methasone
US3678137A (en) * 1970-10-15 1972-07-18 Smith Kline French Lab Adamantyl-substituted-alkyl 2-aminoethyl phosphates and phosphonates
SE378109B (es) * 1972-05-19 1975-08-18 Bofors Ab
US3975391A (en) * 1973-12-26 1976-08-17 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US4068076A (en) * 1972-12-29 1978-01-10 Otsuka Pharmaceutical Co., Ltd. 5-(1-Hydroxy-2-(heterocyclic amino))ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
JPS5649907B2 (es) * 1974-02-01 1981-11-25
US4022784A (en) * 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-substituted-carbostyril and -3,4-dihydrocarbostyril derivatives
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US4145542A (en) * 1974-06-13 1979-03-20 Otsuka Pharmaceutical Co., Ltd. 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US3994901A (en) * 1974-06-13 1976-11-30 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
EP0006735B1 (en) * 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
US4582855A (en) * 1981-11-12 1986-04-15 American Hospital Supply Corporation Aromatic and esters of hydroxypropylamines
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
JPH0228141A (ja) * 1987-11-13 1990-01-30 Glaxo Group Ltd フェネタノールアミン誘導体
DE3927170A1 (de) * 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
CA2024789C (en) 1989-09-07 2001-02-06 Malcolm Johnson Compounds for the treatment of inflammation and allergy
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) * 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
ATE164525T1 (de) 1990-09-26 1998-04-15 Pharmachemie Bv Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
JP2924924B2 (ja) 1992-12-18 1999-07-26 シェリング・コーポレーション 粉末薬物のための吸入器
EP1547636A1 (en) 1995-04-14 2005-06-29 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
BR9608997A (pt) 1995-06-21 1999-06-29 Asta Medica Ag Cartucho para pó farmacêutico com dispositivo de medição integrado e intalador para medicamentos em pó
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
AU4248597A (en) 1996-09-06 1998-03-26 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
AUPP549998A0 (en) * 1998-08-26 1998-09-17 Fujisawa Pharmaceutical Co., Ltd. New compound
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
ATE416184T1 (de) * 2000-08-05 2008-12-15 Glaxo Group Ltd 17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente
AUPR034000A0 (en) * 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
PL393155A1 (pl) * 2001-09-14 2011-03-28 Glaxo Group Limited Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
JP2005523920A (ja) * 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
PL1730103T3 (pl) * 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
JP2008501705A (ja) * 2004-06-03 2008-01-24 セラヴァンス， インコーポレーテッド ジアミンβ２アドレナリン作用性レセプターアゴニスト
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2008507532A (ja) * 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.

Also Published As

Publication number Publication date
US20110028442A1 (en) 2011-02-03
AU2009218688A1 (en) 2009-09-03
KR20100138886A (ko) 2010-12-31
CA2716397A1 (en) 2009-09-03
EP2096105A1 (en) 2009-09-02
IL206236A0 (en) 2010-12-30
ECSP10010431A (es) 2010-09-30
CN101939291A (zh) 2011-01-05
JP2011517316A (ja) 2011-06-02
RU2010139571A (ru) 2012-04-10
ZA201004009B (en) 2011-02-23
WO2009106351A1 (en) 2009-09-03
CO6251284A2 (es) 2011-02-21
EP2254860A1 (en) 2010-12-01
NZ586049A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
MX2010008864A (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta 2.
MX2010005623A (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta 2.
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
RU2014117188A (ru) Способ получения производных 4,4-дифтор-3,4-дигидроизохинолина
EA201490722A1 (ru) ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
WO2008046598A8 (en) DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR
CR10034A (es) Derivados de oxadiazol
UY31603A1 (es) Derivados de ftalazinona
JP2010527915A5 (es)
TN2011000422A1 (en) Benzofuran derivatives
MX2007009353A (es) Ciclohexilamidas como antagonistas de la dopamina d3, d2 y 5ht1a.
CY1116388T1 (el) 5-(φαινυλο/πυριδινυλο-αιθινυλο)-2-πυριδινο/2-πυριμιδινο-καρβοξαμιδια ως mglur5 ρυθμιστες
EA201390939A1 (ru) Новое замещенное производное изохинолина
MX2012008055A (es) Agente profilactico o de mejoramiento para la pigmentacion.
EA201391538A1 (ru) Производные пиразолидин-3-она
EP2410380A3 (en) Electrophotographic photoreceptor
MX2013008595A (es) Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina.
CY1117212T1 (el) Εθυνυλο παραγωγα ως μεταβοτροπικοι ρυθμιστες του υποδοχεα γλουταμινικου
PH12013500605B1 (en) 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer
NI201300011A (es) Formulaciones
WO2006092507A8 (fr) Derives de 1 ,2,4-triazines, leur preparation et leur application en therapeutique humaine
EA201290681A1 (ru) Синтетическое промежуточное соединение производного оксазола и способ его получения
SG166757A1 (en) Thermoplastic polymer composition and production method thereof
AR076276A1 (es) Derivados de n-[(7-aza-biciclo[2.2.1]hept-1-il)-aril-metil]-benzamida, su prepara-cion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal